Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Seltorexant Formulations in Healthy Subjects
NCT03438461Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of seltorexant in major depressive disorder (MDD) and Insomnia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area Under the Plasma Concentration-Time Curve from Time 0 to Last Measurable Concentration at 48 hours and 2 more. Started Feb 2018; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT03438461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03438461.